This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
by Zacks Equity Research
CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
by Zacks Equity Research
HUM's second-quarter earnings are likely to have witnessed strength in insurance premiums and Medicare, partly offset by rising costs and membership declines.
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
by Zacks Equity Research
CNC reports rare Q2 loss amid surging medical costs, lower investment and other income despite strong revenue growth.
Durable Goods Orders Contract in June
by Zacks Equity Research
Durable Goods Orders Contract in June.
Pre-Markets Moderate in the Green for Another Up-Week
by Mark Vickery
Over the past week of trading -- which has been positive across the board -- we're seeing a bit of moderation at or near all-time highs.
Centene (CNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -123.53% and +10.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Bear of the Day: Centene (CNC)
by Kevin Cook
Managed care giant takes a 50% haircut on projected EPS after an unfavorable study of its insurance markets
CyberArk and Centene have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CyberArk debuts AI agent security tools amid soaring enterprise demand, while Centene slashes guidance on risk data shock.
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
by Zacks Equity Research
CNC's Q2 earnings are likely to have felt the pinch as rising medical costs pressure margins despite higher premium revenues.
Analysts Estimate UnitedHealth Group (UNH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
UnitedHealth (UNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Centene (CNC) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Centene (CNC) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts Estimate Centene (CNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?
by Kaibalya Pravo Dey
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
Billing or Healing? UnitedHealth's HouseCalls Get a DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a DOJ criminal probe over its HouseCalls billing, raising stakes for the Medicare Advantage giant.
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
by Kaibalya Pravo Dey
MOH slashes 2025 EPS outlook by more than 10%, citing rising medical costs and echoing warnings from CNC and UnitedHealth.
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
by Kaibalya Pravo Dey
UNH and peers tumble as Medicaid cuts, enrollment shifts and rising costs shake up the managed care sector.
Humana Expands Medicaid Footprint With Virginia's Cardinal Care Win
by Zacks Equity Research
Cardinal Care taps HUM to offer its Healthy Horizons Medicaid plan, unlocking new growth in Virginia's healthcare market.
Zacks.com featured highlights include Hudbay Minerals, StoneCo, Centene and CVS Health
by Zacks Equity Research
HBM, STNE, CNC, and CVS stand out for low P/CF ratios and strong value scores as investors seek quality in a cautious market.
Company News for Jul 3, 2025
by Zacks Equity Research
Companies In The News Are: GBX, UNF, CNC, HOOD.
Centene Pulls 2025 Guidance as Marketplace Growth Falters
by Zacks Equity Research
CNC pulls its 2025 forecast after a $1.8B risk adjustment shortfall. Also, weak Marketplace growth shakes investor confidence.
These Top 4 Women-Run Company Stocks Are Quietly Beating the Market
by Shrabana Mukherjee
These women-run company stocks offer high growth and stability.
4 Value Stocks to Invest in for the Second-Half 2025 Market Shift
by Sumit Singh
Hudbay, StoneCo, Centene, and CVS stand out as top value picks for H2 2025 with strong cash flow and growth prospects.
Is Centene (CNC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, ODP, STNE and PSFE are some such stocks.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.